Aurobindo Pharma Management
Management criteria checks 3/4
Aurobindo Pharma's CEO is Kambam Reddy, appointed in Jun 2006, has a tenure of 18.42 years. total yearly compensation is ₹45.05M, comprised of 50.9% salary and 49.1% bonuses, including company stock and options. directly owns 5.61% of the company’s shares, worth ₹40.28B. The average tenure of the management team and the board of directors is 9.5 years and 5.5 years respectively.
Key information
Kambam Reddy
Chief executive officer
₹45.0m
Total compensation
| CEO salary percentage | 50.9% |
| CEO tenure | 18.4yrs |
| CEO ownership | 5.6% |
| Management average tenure | 9.5yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts
Nov 12
Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price
Oct 20Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Sep 10This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422
Aug 13Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
May 22Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹36b |
| Jun 30 2024 | n/a | n/a | ₹35b |
| Mar 31 2024 | ₹45m | ₹23m | ₹32b |
| Dec 31 2023 | n/a | n/a | ₹28b |
| Sep 30 2023 | n/a | n/a | ₹23b |
| Jun 30 2023 | n/a | n/a | ₹20b |
| Mar 31 2023 | ₹37m | ₹19m | ₹19b |
| Dec 31 2022 | n/a | n/a | ₹20b |
| Sep 30 2022 | n/a | n/a | ₹21b |
| Jun 30 2022 | n/a | n/a | ₹24b |
| Mar 31 2022 | ₹27m | ₹14m | ₹26b |
| Dec 31 2021 | n/a | n/a | ₹29b |
| Sep 30 2021 | n/a | n/a | ₹52b |
| Jun 30 2021 | n/a | n/a | ₹53b |
| Mar 31 2021 | ₹23m | ₹20m | ₹53b |
| Dec 31 2020 | n/a | n/a | ₹54b |
| Sep 30 2020 | n/a | n/a | ₹31b |
| Jun 30 2020 | n/a | n/a | ₹30b |
| Mar 31 2020 | ₹15m | ₹13m | ₹28b |
| Dec 31 2019 | n/a | n/a | ₹26b |
| Sep 30 2019 | n/a | n/a | ₹26b |
| Jun 30 2019 | n/a | n/a | ₹25b |
| Mar 31 2019 | ₹15m | ₹13m | ₹24b |
| Dec 31 2018 | n/a | n/a | ₹23b |
| Sep 30 2018 | n/a | n/a | ₹22b |
| Jun 30 2018 | n/a | n/a | ₹24b |
| Mar 31 2018 | ₹15m | ₹13m | ₹24b |
Compensation vs Market: Kambam's total compensation ($USD533.60K) is below average for companies of similar size in the Indian market ($USD776.13K).
Compensation vs Earnings: Kambam's compensation has increased by more than 20% in the past year.
CEO
Kambam Reddy (66 yo)
18.4yrs
Tenure
₹45,048,542
Compensation
Mr. Kambam Nithyananda Reddy has been Vice Chairman of Aurobindo Pharma Limited since June 1, 2012 and serves as a Whole Time Director of Aurobindo Pharma Limited since December 26, 1986 and serves as Mana...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & MD | 18.4yrs | ₹45.05m | 5.61% ₹ 40.3b | |
| Whole-Time Director | no data | ₹60.15m | no data | |
| President of Biologics | 8.8yrs | ₹300.00k | no data | |
| Chief Financial Officer | 10.3yrs | ₹21.06m | no data | |
| President of Technical | no data | no data | no data | |
| Compliance Officer & Company Secretary | 8.4yrs | ₹4.76m | no data | |
| Senior Vice President of Global Finance & Operations | no data | no data | no data | |
| Head of Global Finance Operations | no data | no data | no data | |
| Chief Quality Officer -Corporate QA | no data | no data | 0.025% ₹ 176.7m | |
| President of Chemical Research | no data | no data | no data | |
| President of RAD-II | no data | ₹9.14m | no data | |
| President-ARD | no data | ₹10.09m | no data |
9.5yrs
Average Tenure
60yo
Average Age
Experienced Management: AUROPHARMA's management team is seasoned and experienced (9.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & MD | 37.9yrs | ₹45.05m | 5.61% ₹ 40.3b | |
| Whole-Time Director | 18.2yrs | ₹60.15m | no data | |
| President of Biologics | less than a year | ₹300.00k | no data | |
| Non-Executive Director | 37.9yrs | ₹600.00k | 3.07% ₹ 22.0b | |
| Non-Executive Director | 17.2yrs | ₹900.00k | no data | |
| Independent Director | 1.8yrs | ₹2.50m | no data | |
| Independent Director | no data | ₹500.00k | no data | |
| Additional Non-Executive Independent Director | 6.9yrs | ₹2.20m | no data | |
| Independent Director of Apitoria Pharma Private Limited | 1.6yrs | no data | no data | |
| Independent Non-Executive Chairman | less than a year | no data | no data | |
| Non-Executive Independent Director | 4yrs | ₹2.60m | no data |
5.5yrs
Average Tenure
64yo
Average Age
Experienced Board: AUROPHARMA's board of directors are considered experienced (5.5 years average tenure).